Information Provided By: 
Fly News Breaks for April 19, 2017
RARE
Apr 19, 2017 | 07:08 EDT
Cowen analyst Arlinda Lee noted Ultragenyx Phase 3 drug candidate KRN23 for stiffness associated with adult X-linked hypophosphatemia met its primary endpoint, as expected, and also showed clinically meaningful benefit in key secondary endpoints in the trial. The analyst said the company's additional drug candidates also remain attractive and with upcoming catalysts, Lee reiterated her Outperform rating and $100 price target on Ultragenyx shares.
News For RARE From the Last 2 Days
